Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834574 · ClinicalTrials.gov registry record · Phase 1
Cefdinir for Oral Suspension 250 mg/5mL, Fasting
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00834574: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00834574 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00834574, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The objective of this study is to compare the relative bioavailability of cefdinir for oral suspension 250 mg/5mL (manufactured and distributed by TEVA Pharmaceuticals USA) with that of OMNICEF® for oral suspension, 250 mg/5mL (Abbott) in healthy, adult, non-smoking subjects under fasting conditions.
Interventions
- DRUG Cefdinir for oral suspension 250 mg/5mL
- DRUG OMNICEF® for oral suspension 250 mg/5mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00834574
The ClinicalTrials.gov registry entry for NCT00834574 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cefdinir for oral suspension 250 mg/5mL is the first listed.
NCT00834574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00834574 about?
NCT00834574 is a clinical study titled "Cefdinir for Oral Suspension 250 mg/5mL, Fasting". The objective of this study is to compare the relative bioavailability of cefdinir for oral suspension 250 mg/5mL (manufactured and distributed by TEVA Pharmaceuticals USA) with that of OMNICEF® for oral suspension, 250 mg/5mL (Abbott) in healthy, adult, non-smoking subjects under fasting conditions...
What is the current status of trial NCT00834574?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2005-02. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00834574?
The interventions under investigation include: Cefdinir for oral suspension 250 mg/5mL (DRUG), OMNICEF® for oral suspension 250 mg/5mL (DRUG).
Who is sponsoring clinical trial NCT00834574?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.